Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novavax (NVAX – Research Report) and PharmaCyte Biotech (PMCB – Research Report).
Novavax (NVAX)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Novavax, with a price target of $207.00. The company’s shares closed last Monday at $67.15, close to its 52-week low of $34.88.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
Currently, the analyst consensus on Novavax is a Moderate Buy with an average price target of $126.50, which is an 88.4% upside from current levels. In a report issued on June 28, Jefferies also maintained a Buy rating on the stock with a $190.00 price target.
See the top stocks recommended by analysts >>
PharmaCyte Biotech (PMCB)
H.C. Wainwright analyst Edward White maintained a Hold rating on PharmaCyte Biotech today. The company’s shares closed last Monday at $2.38, close to its 52-week low of $1.79.
According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for PharmaCyte Biotech.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NVAX:
- Elon Musk’s Response Tanks Twitter Stock by 11%
- Moderna (MRNA) Gets a Buy Rating from Brookline Capital Markets
- Axcelis Technologies (ACLS) Gets a Buy Rating from Benchmark Co.
- Uber is Likely to Ride Out the Challenging Environment, Says Analyst
- Jefferies Thinks Clarivate’s Stock is Going to Recover
